BRPI0711767B8 - composição farmacêutica transportadora de no gasoso sanguíneo, uso de uma proteína h-nox, kit, proteína de hnox recombinante e ácido nucléico recombinante - Google Patents

composição farmacêutica transportadora de no gasoso sanguíneo, uso de uma proteína h-nox, kit, proteína de hnox recombinante e ácido nucléico recombinante

Info

Publication number
BRPI0711767B8
BRPI0711767B8 BRPI0711767A BRPI0711767A BRPI0711767B8 BR PI0711767 B8 BRPI0711767 B8 BR PI0711767B8 BR PI0711767 A BRPI0711767 A BR PI0711767A BR PI0711767 A BRPI0711767 A BR PI0711767A BR PI0711767 B8 BRPI0711767 B8 BR PI0711767B8
Authority
BR
Brazil
Prior art keywords
protein
recombinant
nox
hnox
kit
Prior art date
Application number
BRPI0711767A
Other languages
English (en)
Portuguese (pt)
Inventor
M Boon Elizabeth
A Winger Jonathan
A Marletta Michael
P L Cary Stephen
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BRPI0711767A2 publication Critical patent/BRPI0711767A2/pt
Publication of BRPI0711767B1 publication Critical patent/BRPI0711767B1/pt
Publication of BRPI0711767B8 publication Critical patent/BRPI0711767B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/102499—Blood gas standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0711767A 2006-05-22 2007-05-21 composição farmacêutica transportadora de no gasoso sanguíneo, uso de uma proteína h-nox, kit, proteína de hnox recombinante e ácido nucléico recombinante BRPI0711767B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92150506P 2006-05-22 2006-05-22
US60/921,505 2006-05-22
US60/921.505 2006-05-22
PCT/US2007/012133 WO2007139767A2 (en) 2006-05-22 2007-05-21 Compositions and methods for the delivery of nitric oxide

Publications (3)

Publication Number Publication Date
BRPI0711767A2 BRPI0711767A2 (pt) 2012-01-10
BRPI0711767B1 BRPI0711767B1 (pt) 2018-05-15
BRPI0711767B8 true BRPI0711767B8 (pt) 2021-05-25

Family

ID=38779160

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0711901-1A BRPI0711901A2 (pt) 2006-05-22 2007-05-21 Composições e métodos para a liberação de oxigênio
BRPI0711767A BRPI0711767B8 (pt) 2006-05-22 2007-05-21 composição farmacêutica transportadora de no gasoso sanguíneo, uso de uma proteína h-nox, kit, proteína de hnox recombinante e ácido nucléico recombinante

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0711901-1A BRPI0711901A2 (pt) 2006-05-22 2007-05-21 Composições e métodos para a liberação de oxigênio

Country Status (12)

Country Link
US (7) US8404632B2 (enExample)
EP (7) EP2040740B1 (enExample)
JP (5) JP5698905B2 (enExample)
CN (5) CN101495134B (enExample)
AU (2) AU2007268052B2 (enExample)
BR (2) BRPI0711901A2 (enExample)
CA (2) CA2653101C (enExample)
DK (4) DK2463297T3 (enExample)
ES (4) ES2611157T3 (enExample)
IN (2) IN2013MN00600A (enExample)
NZ (4) NZ594456A (enExample)
WO (2) WO2007139791A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5698905B2 (ja) 2006-05-22 2015-04-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 一酸化窒素の送達のための方法
US20110243849A1 (en) * 2010-04-02 2011-10-06 Marletta Michael A Heme-binding photoactive polypeptides and methods of use thereof
JP6322652B2 (ja) * 2013-01-07 2018-05-09 オムニオクス， インコーポレイテッド Ｈ−ｎｏｘタンパク質の重合体形態
SG10201908269SA (en) * 2015-03-17 2019-10-30 Omniox Inc Modulation of tumor immunity by protein-mediated o2 delivery
DK3416673T3 (da) * 2016-02-16 2023-01-23 Omniox Inc Modulation af hypoxi associeret med slagtilfælde
JP6467073B2 (ja) * 2018-01-04 2019-02-06 オムニオクス， インコーポレイテッド Ｈ−ｎｏｘタンパク質の重合体形態
WO2020037052A1 (en) 2018-08-15 2020-02-20 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions
KR20210052389A (ko) 2018-08-27 2021-05-10 리제너론 파마슈티칼스 인코포레이티드 다운스트림 정제에서의 라만 분광법의 사용
UA129329C2 (uk) 2019-06-25 2025-03-19 Гіліад Сайєнсіз, Інк. ЗЛИТІ БІЛКИ FLT3L-Fc
CN118178645A (zh) 2019-10-18 2024-06-14 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
AU2020412875A1 (en) 2019-12-24 2022-06-23 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
PH12022552122A1 (en) 2020-02-14 2024-01-29 Jounce Therapeutics Inc Antibodies and fusion proteins that bind to ccr8 and uses thereof
AU2021264550A1 (en) 2020-05-01 2022-11-17 Gilead Sciences, Inc. CD73 inhibiting 2,4-dioxopyrimidine compounds
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
ES2999273T3 (en) 2022-03-17 2025-02-25 Gilead Sciences Inc Ikaros zinc finger family degraders and uses thereof
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
KR20250004824A (ko) 2022-04-21 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Kras g12d 조절 화합물
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250100998A1 (en) 2023-07-26 2025-03-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6022849A (en) 1987-05-16 2000-02-08 Baxter Biotech Technology Saarl Mutant recombinant hemoglobins containing heme pocket mutations
US5731454A (en) 1990-02-12 1998-03-24 Virginia Commonwealth University Allosteric modifiers of hemoglobin useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
WO1995027040A1 (en) 1994-04-01 1995-10-12 Unisyn Technologies, Inc. Culture media additives for hollow fiber bioreactors
JP4583510B2 (ja) 1997-02-28 2010-11-17 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 無細胞系による酸素輸送の最適化のための方法と組成物
DE69839263T2 (de) 1997-05-02 2009-04-30 Baxter Biotech Technology S.A.R.L. Hämoglobin-Mutanten mit verringertem Stickstoff(mon)oxid-Entfernungsvermögen
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
US6773613B1 (en) 1998-10-15 2004-08-10 Sangart, Inc. Method for production of stroma-free hemoglobin
DE60038631T2 (de) * 1999-12-22 2009-06-10 The Scripps Research Institute, La Jolla Modulatoren und inhibitoren von angiogenese und vaskulärer durchlässigkeit
AU2001271536A1 (en) * 2000-06-29 2002-01-14 Incyte Genomics, Inc. Adenylyl and guanylyl cyclases
US20030096240A1 (en) * 2000-09-19 2003-05-22 Ferid Murad Genomic organization of mouse and human sGC
US6780849B2 (en) * 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
DE60333306D1 (de) * 2002-08-30 2010-08-19 Biorexis Pharmaceutical Corp Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy-terminalen domänen
CN1660100A (zh) * 2002-12-09 2005-08-31 上海倍艺医药科技有限公司 一种治疗糖尿病及其并发症的药物
JP5698905B2 (ja) * 2006-05-22 2015-04-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 一酸化窒素の送達のための方法

Also Published As

Publication number Publication date
US20130288970A1 (en) 2013-10-31
NZ594457A (en) 2013-06-28
AU2007268028B2 (en) 2013-03-14
JP2015007108A (ja) 2015-01-15
AU2007268052B2 (en) 2013-07-04
US8404632B2 (en) 2013-03-26
EP2040740A2 (en) 2009-04-01
NZ573003A (en) 2012-06-29
JP2009538134A (ja) 2009-11-05
CA2653080C (en) 2019-02-12
BRPI0711767A2 (pt) 2012-01-10
JP5698906B2 (ja) 2015-04-08
EP2463297B1 (en) 2016-10-19
DK2463294T3 (en) 2017-01-16
EP2463294B1 (en) 2016-10-19
IN2013MN00600A (enExample) 2015-06-12
JP5698905B2 (ja) 2015-04-08
DK2032156T3 (da) 2013-02-18
EP2474554A2 (en) 2012-07-11
ES2610653T3 (es) 2017-04-28
JP2014224156A (ja) 2014-12-04
BRPI0711901A2 (pt) 2012-03-06
JP2017137337A (ja) 2017-08-10
CA2653101C (en) 2016-12-13
EP2032156A2 (en) 2009-03-11
JP6118772B2 (ja) 2017-04-19
US20100285104A1 (en) 2010-11-11
CA2653080A1 (en) 2007-12-06
ES2611157T3 (es) 2017-05-05
JP6458070B2 (ja) 2019-01-23
US20150376250A1 (en) 2015-12-31
EP2463297A1 (en) 2012-06-13
BRPI0711767B1 (pt) 2018-05-15
DK2463297T3 (en) 2017-01-09
JP6118296B2 (ja) 2017-04-19
CN104689300A (zh) 2015-06-10
WO2007139791A2 (en) 2007-12-06
DK2040740T3 (en) 2014-12-01
EP2032156A4 (en) 2009-11-11
US20130289252A1 (en) 2013-10-31
ES2399662T3 (es) 2013-04-02
CN108273040A (zh) 2018-07-13
CN104689300B (zh) 2018-06-05
EP2463295A1 (en) 2012-06-13
EP2040740B1 (en) 2014-09-03
CN101495506A (zh) 2009-07-29
EP2474554A3 (en) 2012-10-03
WO2007139767A3 (en) 2008-02-07
US20170267732A1 (en) 2017-09-21
JP2009538133A (ja) 2009-11-05
EP2463294A1 (en) 2012-06-13
EP2032156B1 (en) 2012-11-21
US9493527B2 (en) 2016-11-15
WO2007139767A2 (en) 2007-12-06
CN101495134A (zh) 2009-07-29
CN101495134B (zh) 2016-08-03
US20150266931A1 (en) 2015-09-24
CN106075388B (zh) 2021-06-29
CA2653101A1 (en) 2007-12-06
AU2007268052A1 (en) 2007-12-06
CN106075388A (zh) 2016-11-09
HK1129688A1 (en) 2009-12-04
IN2013MN00601A (enExample) 2015-06-12
NZ594456A (en) 2013-06-28
WO2007139791A3 (en) 2008-05-02
CN101495506B (zh) 2016-08-10
US8404631B2 (en) 2013-03-26
EP2463296A1 (en) 2012-06-13
US9493526B2 (en) 2016-11-15
EP2040740A4 (en) 2009-10-21
US20100266673A1 (en) 2010-10-21
US10202428B2 (en) 2019-02-12
NZ573004A (en) 2012-06-29
AU2007268028A1 (en) 2007-12-06
ES2525226T3 (es) 2014-12-19

Similar Documents

Publication Publication Date Title
BRPI0711767B8 (pt) composição farmacêutica transportadora de no gasoso sanguíneo, uso de uma proteína h-nox, kit, proteína de hnox recombinante e ácido nucléico recombinante
TR200807263T1 (tr) IgG'nin FcRn'ye bağlanmasını bloke eden peptidler
PE20140232A1 (es) Proteinas de enlace antigeno capaz de enlazar linfopoyetina estromal timica
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
EA200870594A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
ATE537188T1 (de) Serumalbuminbindende proteine
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
UA100682C2 (ru) АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
DE602008002810D1 (de) Peptide zur desensibilisierung gegenüber allergenen
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
IN2012DN03368A (enExample)
SG165339A1 (en) Incorporation of non-naturally encoded amino acids into proteins
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
MX2010000410A (es) Termoestabilizacion de proteinas.
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
GB2443978A (en) Methods for the detection of colorectal cancer
BR112013031056A2 (pt) peptídeos de sema5b e vacinas incluindo os mesmos
BRPI1013956B8 (pt) método para isolar uma proteína recombinante, partículas secas por aspersão, composição, e, uso de partículas secas por aspersão
WO2007089923A3 (en) Modifications of cst-ii for increased protein expression
PL2255834T3 (pl) Projektowanie rusztowania z zastosowaniem czynników zasiedlania
ATE542831T1 (de) Neue antigene und antikörper, die mit adenokarzinomen des pankreasgangs assoziiert sind
WO2007047653A3 (en) Synthetic hla binding peptide analogues of mutant v617f jak2 enzyme and uses therefor
WO2005000870A3 (en) Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof
BR112012014345A2 (pt) peptídeos tmem22 e vacinas incluindo os mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/05/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF